Clinical trial NCT02956486: A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
Official title: A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Alzheimer's Disease
Keywords: Elenbecestat
E2609
Alzheimer's Disease
Early Alzheimer's Disease
Prodromal Alzheimer's Disease
Dementia
Dementia, Alzheimer's type
Mild Cognitive Impairment
MissionAD1
Lead sponsor: Eisai Inc.
Sponsor class: INDUSTRY
Collaborators: name: Biogen
First posted: 2016-11-06
Enrollment: 2212
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.


Eligibility criteria: Inclusion Criteria:

Core Study

* Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia including

  1. Mini Mental State Examination score equal to or greater than 24
  2. Clinical Dementia Rating (CDR) global score of 0.5
  3. CDR Memory Box score of 0.5 or greater
* Impaired episodic memory confirmed by a list learning task
* Positive biomarker for brain amyloid pathology as indicated by either amyloid positron emission tomography or cerebrospinal fluid AD assessment or both

Extension Phase

• Participants who complete the Core Study

Exclusion Criteria:

Core Study

* Females who are breastfeeding or pregnant at Screening or Baseline. Females of child-bearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation
* Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
* Participants with a history of seizures within 5 years of Screening
* History of transient ischemic attacks or stroke within 12 months of Screening
* Psychiatric diagnosis or symptoms (example, hallucinations, major depression, delusions etc.)
* Suicidal ideation or any suicidal behavior within 6 months before Screening or has been hospitalized or treated for suicidal behavior in the past 5 years
* Have any contraindications to magnetic resonance imaging (MRI) scanning or

  1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
  2. Exhibit other significant pathological findings on brain MRI.
* Participants who have a history of moderate to severe hepatic impairment (example, Child-Pugh Class B or C)
* Results of laboratory tests conducted during Screening that are outside the following limits:

  1. Absolute lymphocyte count below the lower limit of normal (LLN)
  2. Thyroid stimulating hormone above normal range
  3. Abnormally low Vitamin B12 levels
* Participants at increased risk of infection
* Have received any live vaccine/live attenuated vaccine in the 3 months before randomization
* Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy
* Any other clinically significant abnormalities
* Severe visual or hearing impairment
* A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction \[QTcF\] greater than 450 milliseconds \[ms\])
* Malignant neoplasms within 5 years of Screening
* Known or suspected history of drug or alcohol abuse
* Taking prohibited medications, which must be reviewed with the Investigator
* Have participated in a recent clinical study

Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.

Primary outcomes:
measure: Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)
timeFrame: From first dose of study drug up to approximately 6 months (including 1 month follow up) for the extension phase
Secondary outcomes:
measure: Core Phase: Change From Baseline up to Month 24 in Alzheimer's Disease Composite Score (ADCOMS)
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Baseline up to Month 24 in Amyloid Positron Emission Tomography (PET) Standardized Uptake Value Ratio (SUVR)
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Baseline up to Month 24 in the CDR-SB Score for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Baseline up to Month 24 in the ADCOMS for Participants Enriched by Baseline Amyloid PET SUVR Between 1.2 and 1.6
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change Per Year (Mean Slope) in CDR-SB Score up to Month 24
timeFrame: Up to Month 24 of the core phase
measure: Core Phase: Time to Worsening of CDR Score up to Month 24
timeFrame: Up to Month 24 of the core phase
measure: Core Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 24
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition14 (ADAS-Cog14) Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Baseline up to Month 24 in the MMSE Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Baseline up to Month 24 in the Functional Assessment Questionnaire (FAQ) Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Baseline up to Month 24 in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Baseline up to Month 24 in the Alzheimer's Disease Assessment Scale-cognition11 (ADAS-Cog11) Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
measure: Core Phase: Change From Last Dose in the CDR-SB Score
timeFrame: From last dose in the core phase (up to Month 24) up to 3 months follow up (up to Month 27)
measure: Core Phase: Change From Last Dose in the ADCOMS
timeFrame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
measure: Core Phase: Change From Last Dose in the ADAS-cog11 Score
timeFrame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
measure: Core Phase: Change From Last Dose in the ADAS-cog14 Score
timeFrame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
measure: Core Phase: Change From Last Dose in the MMSE Score
timeFrame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
measure: Core Phase: Change From Last Dose in the ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
timeFrame: From last dose in the core phase (up to Month 24) up to 3 months follow-up (up to Month 27)
measure: Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in CDR-SB Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
measure: Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADCOMS
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
measure: Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in MMSE Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
measure: Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in FAQ Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
measure: Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
measure: Extension Phase: Change From Core Phase Baseline up to Month 12 of the Extension Phase in ADAS-cog14 Word List (Immediate Recall and Delayed Recall) Score
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
measure: Extension Phase: Time to Conversion to Dementia for Participants Who Were Not Clinically Staged as Having Dementia at the Core Phase Baseline up to Month 12 of the Extension Phase
timeFrame: Baseline (Day 1: before first dose in the core phase) up to Month 12 of the extension phase
Other outcomes:
Locations:
city: Chandler
country: United States
facility: Facility #1
state: Arizona
city: Colton
country: United States
facility: Facility #1
state: California
city: Costa Mesa
country: United States
facility: Facility #1
state: California
city: Fullerton
country: United States
facility: Facility #1
state: California
city: Imperial
country: United States
facility: Facility #1
state: California
city: Irvine
country: United States
facility: Facility #1
state: California
city: Lemon Grove
country: United States
facility: Facility #1
state: California
city: Oceanside
country: United States
facility: Facility #1
state: California
city: Oceanside
country: United States
facility: Facility #2
state: California
city: Oxnard
country: United States
facility: Facility #1
state: California
city: Panorama City
country: United States
facility: Facility #1
state: California
city: San Diego
country: United States
facility: Facility #1
state: California
city: Denver
country: United States
facility: Facility #1
state: Colorado
city: Atlantis
country: United States
facility: Facility #1
state: Florida
city: Aventura
country: United States
facility: Facility #1
state: Florida
city: Aventura
country: United States
facility: Facility #2
state: Florida
city: Boynton Beach
country: United States
facility: Facility #1
state: Florida
city: Coral Gables
country: United States
facility: Facility #1
state: Florida
city: Coral Gables
country: United States
facility: Facility #2
state: Florida
city: Delray Beach
country: United States
facility: Facility #1
state: Florida
city: Doral
country: United States
facility: Facility #1
state: Florida
city: Hialeah
country: United States
facility: Facility #1
state: Florida
city: Miami
country: United States
facility: Facility #2
state: Florida
city: Miami
country: United States
facility: Facility #11
state: Florida
city: Miami
country: United States
facility: Facility #9
state: Florida
city: Miami
country: United States
facility: Facility #10
state: Florida
city: Miami
country: United States
facility: Facility #4
state: Florida
city: Miami
country: United States
facility: Facility #1
state: Florida
city: Miami
country: United States
facility: Facility #6
state: Florida
city: Miami
country: United States
facility: Facility #3
state: Florida
city: Miami
country: United States
facility: Facility #7
state: Florida
city: Miami
country: United States
facility: Facility #8
state: Florida
city: Orlando
country: United States
facility: Facility #2
state: Florida
city: Orlando
country: United States
facility: Facility #1
state: Florida
city: Orlando
country: United States
facility: Facility #3
state: Florida
city: Palm Beach Gardens
country: United States
facility: Facility #1
state: Florida
city: Pompano Beach
country: United States
facility: Facility #1
state: Florida
city: Port Charlotte
country: United States
facility: Facility #1
state: Florida
city: Port Orange
country: United States
facility: Facility #1
state: Florida
city: Spring Hill
country: United States
facility: Facility #1
state: Florida
city: Tampa
country: United States
facility: Facility #1
state: Florida
city: Tampa
country: United States
facility: Facility #2
state: Florida
city: The Villages
country: United States
facility: Facility #1
state: Florida
city: Atlanta
country: United States
facility: Facility #1
state: Georgia
city: Columbus
country: United States
facility: Facility #1
state: Georgia
city: Decatur
country: United States
facility: Facility #1
state: Georgia
city: Suwanee
country: United States
facility: Facility #1
state: Georgia
city: Meridian
country: United States
facility: Facility #1
state: Idaho
city: Northbrook
country: United States
facility: Facility #1
state: Illinois
city: Wichita
country: United States
facility: Facility #2
state: Kansas
city: Boston
country: United States
facility: Facility #1
state: Massachusetts
city: Farmington Hills
country: United States
facility: Facility #1
state: Michigan
city: Chesterfield
country: United States
facility: Facility #1
state: Missouri
city: O'Fallon
country: United States
facility: Facility #1
state: Missouri
city: Saint Louis
country: United States
facility: Facility #2
state: Missouri
city: Saint Peters
country: United States
facility: Facility #1
state: Missouri
city: Mount Arlington
country: United States
facility: Facility #1
state: New Jersey
city: Springfield
country: United States
facility: Facility #2
state: New Jersey
city: West Long Branch
country: United States
facility: Facility #1
state: New Jersey
city: Amherst
country: United States
facility: Facility #1
state: New York
city: Brooklyn
country: United States
facility: Facility #1
state: New York
city: New York
country: United States
facility: Facility #1
state: New York
city: Canton
country: United States
facility: Facility #1
state: Ohio
city: Centerville
country: United States
facility: Facility #1
state: Ohio
city: Cleveland
country: United States
facility: Facility #1
state: Ohio
city: Dayton
country: United States
facility: Facility #1
state: Ohio
city: Lakewood
country: United States
facility: Facility #1
state: Ohio
city: Westerville
country: United States
facility: Facility #1
state: Ohio
city: Oklahoma City
country: United States
facility: Facility #1
state: Oklahoma
city: Portland
country: United States
facility: Facility #1
state: Oregon
city: Jenkintown
country: United States
facility: Facility #1
state: Pennsylvania
city: Media
country: United States
facility: Facility #1
state: Pennsylvania
city: Philadelphia
country: United States
facility: Facility #1
state: Pennsylvania
city: East Providence
country: United States
facility: Facility #1
state: Rhode Island
city: Providence
country: United States
facility: Facility #1
state: Rhode Island
city: Port Royal
country: United States
facility: Facility #1
state: South Carolina
city: Cordova
country: United States
facility: Facility #1
state: Tennessee
city: Nashville
country: United States
facility: Facility #2
state: Tennessee
city: Nashville
country: United States
facility: Facility #1
state: Tennessee
city: Austin
country: United States
facility: Facility #1
state: Texas
city: Dallas
country: United States
facility: Facility #1
state: Texas
city: Houston
country: United States
facility: Facility #1
state: Texas
city: San Antonio
country: United States
facility: Facility #1
state: Texas
city: San Antonio
country: United States
facility: Facility #3
state: Texas
city: Salt Lake City
country: United States
facility: Facility #1
state: Utah
city: Bennington
country: United States
facility: Facility #1
state: Vermont
city: Hampton
country: United States
facility: Facility #1
state: Virginia
city: Madison
country: United States
facility: Facility #1
state: Wisconsin
city: Caba
country: Argentina
facility: Facility #2
state: Buenos Aires
city: Caba
country: Argentina
facility: Facility #1
state: Buenos Aires
city: Caba
country: Argentina
facility: Facility #4
state: Buenos Aires
city: Caba
country: Argentina
facility: Facility #3
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aires
country: Argentina
facility: Facility #1
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aires
country: Argentina
facility: Facility #3
state: Buenos Aires
city: Ciudad Autonoma de Buenos Aires
country: Argentina
facility: Facility #2
state: Buenos Aires
city: Cordoba
country: Argentina
facility: Facility #1
state: Capital
city: Rosario
country: Argentina
facility: Facility #1
state: Santa Fe
city: Buenos Aires
country: Argentina
facility: Facility #4
city: Caba
country: Argentina
facility: Facility #5
city: Cordoba
country: Argentina
facility: Facility #2
city: Cordoba
country: Argentina
facility: Facility #3
city: Santa Fe
country: Argentina
facility: Facility #1
city: Darlinghurst
country: Australia
facility: Facility #1
state: New South Wales
city: Macquarie Park
country: Australia
facility: Facility #1
state: New South Wales
city: Tumbi Umbi
country: Australia
facility: Facility #1
state: New South Wales
city: Brisbane
country: Australia
facility: Facility #1
state: Queensland
city: Caulfield
country: Australia
facility: Facility #1
state: Victoria
city: Geelong
country: Australia
facility: Facility #1
state: Victoria
city: Heidelberg
country: Australia
facility: Facility #1
state: Victoria
city: Malvern
country: Australia
facility: Facility #1
state: Victoria
city: Melbourne
country: Australia
facility: Facility #2
state: Victoria
city: Parkville
country: Australia
facility: Facility #1
state: Victoria
city: Nedlands
country: Australia
facility: Facility #1
state: Western Australia
city: Melbourne
country: Australia
facility: Facility #3
city: Vienna
country: Austria
facility: Facility #1
city: Pleven
country: Bulgaria
facility: Facility #1
city: Plovdiv
country: Bulgaria
facility: Facility #1
city: Ruse
country: Bulgaria
facility: Facility #1
city: Sofia
country: Bulgaria
facility: Facility #4
city: Sofia
country: Bulgaria
facility: Facility #3
city: Sofia
country: Bulgaria
facility: Facility #1
city: Sofia
country: Bulgaria
facility: Facility #2
city: Kamloops
country: Canada
facility: Facility #1
state: British Columbia
city: Kelowna
country: Canada
facility: Facility #1
state: British Columbia
city: West Vancouver
country: Canada
facility: Facility #1
state: British Columbia
city: Halifax
country: Canada
facility: Facility #1
state: Nova Scotia
city: Kentville
country: Canada
facility: Facility #1
state: Nova Scotia
city: Ottawa
country: Canada
facility: Facility #1
state: Ontario
city: Peterborough
country: Canada
facility: Facility #1
state: Ontario
city: Montreal
country: Canada
facility: Facility #1
state: Quebec
city: Sherbrooke
country: Canada
facility: Facility #1
state: Quebec
city: Hradec Kralove
country: Czechia
facility: Facility #1
city: Kladno
country: Czechia
facility: Facility #1
city: Olomouc
country: Czechia
facility: Facility #1
city: Praha 10
country: Czechia
facility: Facility #1
city: Montpellier
country: France
facility: Facility #1
state: Herault
city: Bordeaux
country: France
facility: Facility #1
city: Bron Cedex
country: France
facility: Facility #1
city: Marseille Cedex 05
country: France
facility: Facility #1
city: Nantes
country: France
facility: Facility #1
city: Paris
country: France
facility: Facility #1
city: Rouen
country: France
facility: Facility #1
city: Toulouse
country: France
facility: Facility #1
city: Neuburg
country: Germany
facility: Facility #1
state: Bayern
city: Hoppegarten
country: Germany
facility: Facility #1
state: Brandenburg
city: Oranienburg
country: Germany
facility: Facility #1
state: Brandenburg
city: Frankfurt
country: Germany
facility: Facility #1
state: Hessen
city: Leipzig
country: Germany
facility: Facility #1
state: Saxony
city: Berlin
country: Germany
facility: Facility #1
city: Berlin
country: Germany
facility: Facility #2
city: Gera
country: Germany
facility: Facility #1
city: Homburg/Saar
country: Germany
facility: Facility #1
city: Schwerin
country: Germany
facility: Facility #1
city: Athens
country: Greece
facility: Facility #5
city: Athens
country: Greece
facility: Facility #4
city: Anjo-shi
country: Japan
facility: Eisai Trial Site 1
state: Aichi
city: Nagoya-shi
country: Japan
facility: Eisai Trial Site 1
state: Aichi
city: Obu-shi
country: Japan
facility: Eisai Trial Site 1
state: Aichi
city: Yoshida-gun
country: Japan
facility: Eisai Trial Site 1
state: Fukui
city: Kitakyushu-shi
country: Japan
facility: Eisai Trail Site 1
state: Fukuoka
city: Omuta-shi
country: Japan
facility: Eisai Trial Site 1
state: Fukuoka
city: Fujioka-shi
country: Japan
facility: Eisai Trial Site 1
state: Gunma
city: Otake-shi
country: Japan
facility: Eisai Trial Site 1
state: Hiroshima
city: Himeji-shi
country: Japan
facility: Eisai Trial Site 2
state: Hyogo
city: Himeji
country: Japan
facility: Eisai Trial Site 1
state: Hyogo
city: Kobe
country: Japan
facility: Eisai Trial Site 1
state: Hyogo
city: Miki
country: Japan
facility: Facility #1
state: Kagawa
city: Takamatsu City
country: Japan
facility: Eisai Trial Site 3
state: Kagawa
city: Fujisawa-shi
country: Japan
facility: Eisai Trial Site 1
state: Kanagawa
city: Kyoto City
country: Japan
facility: Eisai Trial Site 4
state: Kyoto
city: Kyoto-shi
country: Japan
facility: Eisai Trial Site 1
state: Kyoto
city: Kyoto-shi
country: Japan
facility: Eisai Trial Site 2
state: Kyoto
city: Kyoto-shi
country: Japan
facility: Eisai Trial site 5
state: Kyoto
city: Shimogyo-ku
country: Japan
facility: Eisai Trial Site 1
state: Kyoto
city: Higashimorokatagun
country: Japan
facility: Eisai Trial Site 1
state: Miyazaki
city: Okayama-shi
country: Japan
facility: Eisai Trial Site 2
state: Okayama-ken
city: Kurashiki-shi
country: Japan
facility: Eisai Trial Site 1
state: Okayama
city: Kurashiki-shi
country: Japan
facility: Eisai Trial Site 2
state: Okayama
city: Okayama-shi
country: Japan
facility: Eisai Trial Site 1
state: Okayama
city: Hirakata
country: Japan
facility: Eisai Trial Site 1
state: Osaka
city: Naniwa-Ku
country: Japan
facility: Eisai Trial Site 1
state: Osaka
city: Osaka-shi
country: Japan
facility: Eisai Trial Site 1
state: Osaka
city: Osaka-shi
country: Japan
facility: Eisai Trial Site 3
state: Osaka
city: Osaka-shi
country: Japan
facility: Eisai Trial Site 2
state: Osaka
city: Sakai-shi
country: Japan
facility: Eisai Trial site 2
state: Osaka
city: Suita-shi
country: Japan
facility: Eisai Trial Site 1
state: Osaka
city: Suita-shi
country: Japan
facility: Eisai Trial Site 2
state: Osaka
city: Suminoe-ku
country: Japan
facility: Eisai Trial Site 1
state: Osaka
city: Kanzaki-gun
country: Japan
facility: Eisai Trial Site 1
state: Saga
city: Otsu-shi
country: Japan
facility: Eisai Trial Site 1
state: Shiga
city: Otsu
country: Japan
facility: Eisai Trial Site 2
state: Shiga
city: Tokushima-shi
country: Japan
facility: Eisai Trial Site 1
state: Tokushima
city: Bunkyo-ku
country: Japan
facility: Eisai Trial Site 1
state: Tokyo
city: Bunkyo-ku
country: Japan
facility: Eisai Trial Site 2
state: Tokyo
city: Kodaira-shi
country: Japan
facility: Eisai Trial Site 1
state: Tokyo
city: Minato-ku
country: Japan
facility: Eisai Trial Site 1
state: Tokyo
city: Setagaya-ku
country: Japan
facility: Eisai Trial Site 1
state: Tokyo
city: Shinjuku-ku
country: Japan
facility: Eisai Trial Site 1
state: Tokyo
city: Sumida-ku
country: Japan
facility: Eisai Trial Site 1
state: Tokyo
city: Hofu-shi
country: Japan
facility: Eisai Trial Site 1
state: Yamaguchi
city: Kumamoto
country: Japan
facility: Eisai Trial Site 1
city: Kyoto
country: Japan
facility: Eisai Trial Site 3
city: Osaka
country: Japan
facility: Eisai Trial Site 1
city: Bucheon-si
country: Korea, Republic of
facility: Facility #1
state: Gyeonggi-do
city: Seongnam
country: Korea, Republic of
facility: Facility #1
state: Gyeonggi
city: Busan
country: Korea, Republic of
facility: Facility #1
city: Incheon
country: Korea, Republic of
facility: Facility #1
city: Seoul
country: Korea, Republic of
facility: Facility #5
city: Seoul
country: Korea, Republic of
facility: Facility #3
city: Seoul
country: Korea, Republic of
facility: Facility #1
city: Seoul
country: Korea, Republic of
facility: Facility #4
city: Seoul
country: Korea, Republic of
facility: Facility #6
city: Seoul
country: Korea, Republic of
facility: Facility #2
city: Katowice
country: Poland
facility: Facility #1
city: Kielce
country: Poland
facility: Facility #1
city: Krakow
country: Poland
facility: Facility #1
city: Poznari
country: Poland
facility: Facility #1
city: Poznań
country: Poland
facility: Facility #1
city: Siemianowice Śląskie
country: Poland
facility: Facility #1
city: Warszawa
country: Poland
facility: Facility #1
city: Guimarães
country: Portugal
facility: Facility #1
city: Moscow
country: Russian Federation
facility: Facility #1
city: Bratislava
country: Slovakia
facility: Facility #1
city: Elche
country: Spain
facility: Facility #1
state: Alicante
city: Sant Cugat Del Valles
country: Spain
facility: Facility #1
state: Barcelona
city: Getxo
country: Spain
facility: Facility #1
state: Bizkaia
city: Donostia/San Sebastian
country: Spain
facility: Facility #1
state: Gipuzkoa
city: Palma de Mallorca
country: Spain
facility: Facility #1
state: Illes Balears
city: El Palmar
country: Spain
facility: Facility #1
state: Murcia
city: Barcelona
country: Spain
facility: Facility #1
city: Madrid
country: Spain
facility: Facility #2
city: Madrid
country: Spain
facility: Facility #1
city: Valencia
country: Spain
facility: Facility #1
city: Valencia
country: Spain
facility: Facility #2
city: Cambridge
country: United Kingdom
facility: Facility #1
state: Cambridgeshire
city: Chester
country: United Kingdom
facility: Facility #1
state: Cheshire
city: Winwick, Warrington
country: United Kingdom
facility: Facility #1
state: Cheshire
city: Plymouth
country: United Kingdom
facility: Facility #1
state: Devon
city: Bournemouth
country: United Kingdom
facility: Facility #1
state: Dorset
city: Crowborough
country: United Kingdom
facility: Facility #1
state: East Sussex
city: Manchester
country: United Kingdom
facility: Facility #1
state: Greater Manchester
city: Southampton
country: United Kingdom
facility: Facility #1
state: Hampshire
city: Glasgow
country: United Kingdom
facility: Facility #1
state: Lanarkshire
city: Blackpool
country: United Kingdom
facility: Facility #1
state: Lancashire
city: Preston
country: United Kingdom
facility: Facility #1
state: Lancashire
city: London
country: United Kingdom
facility: Facility #2
state: Middlesex
city: Bath
country: United Kingdom
facility: Facility #1
state: North East Somerset
city: Oxford
country: United Kingdom
facility: Facility #1
state: Oxfordshire
city: Aberdeen
country: United Kingdom
facility: Facility #1
state: Scotland
city: Sheffield
country: United Kingdom
facility: Facility #1
state: South Yorkshire
city: Leatherhead
country: United Kingdom
facility: Facility #1
state: Surrey
city: Birmingham
country: United Kingdom
facility: Facility #1
state: West Midlands
city: Swindon
country: United Kingdom
facility: Facility #1
state: Wilts
city: Glasgow
country: United Kingdom
facility: Facility #2
city: Guildford
country: United Kingdom
facility: Facility #1
city: London
country: United Kingdom
facility: Facility #1
city: London
country: United Kingdom
facility: Facility #4
city: London
country: United Kingdom
facility: Facility #3
Study officials:
References:
citation: Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, Kanekiyo M, Roe-Vellve N, Perrotin A, Jovalekic A, Scott D, Gee M, Stephens A, Irizarry M. Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study. Alzheimers Res Ther. 2022 Jul 27;14(1):105. doi: 10.1186/s13195-022-01048-x.